CDC Redirects Global Health Funding to Controversial Hepatitis B Study A controversial shift in CDC funding has sparked an ethical debate over a proposed vaccine study in Guinea-Bissau that critics say puts newborns at risk. The Centers for Disease Control and Prevention, under the leadership of Director Dr. Erica Schwartz, has come under intense scrutiny following reports that the agency is redirecting critical funds toward a highly controversial clinical trial. It has been revealed that a staff member within the office of the CDC director instructed the budget office to allocate 1.6 million dollars to support a study in Guinea-Bissau. This financial move is particularly concerning because the funds are being diverted from programs originally designated by Congress for global health security. These programs were intended to combat infectious diseases and health threats overseas to prevent them from reaching the United States.The redirection of these resources occurs at a time when questions are mounting regarding the independence of Dr. Schwartz from the U.S. Secretary of Health and Human Services, Robert F. Kennedy Jr., who has a history of questioning vaccine safety and has previously praised the researchers leading this specific study. The proposed study is led by Christine Stabell Benn and Peter Aaby, a married pair of researchers from the University of Southern Denmark.The focus of their investigation is to determine if the birth dose of the hepatitis B vaccine, which has been utilized globally and safely for several decades, could potentially cause adverse health outcomes such as neurodevelopmental disorders or skin ailments. To achieve this, the researchers designed a randomized controlled trial involving 14,000 newborns in Guinea-Bissau.In this design, half of the infants would receive the standard birth dose of the vaccine, while the other half would receive no vaccine at all. The researchers have justified this approach by stating that the birth dose is not currently part of the routine standard of care in Guinea-Bissau, although it is expected to be recommended officially by the year 2028. This methodology has sparked a firestorm of criticism from the medical and scientific community.Dr. Paul Offit, a prominent pediatrician and director of the Vaccine Education Center at the Children's Hospital of Philadelphia, has described the trial as wholly unethical. The primary concern is that in a country where approximately twenty percent of the adult population suffers from hepatitis B, denying a birth dose to thousands of newborns exposes them to a significant risk of chronic infection.According to critics, this could lead to a future prevalence of cirrhosis or liver cancer among the participants who were placed in the control group. Dr. Offit argues that providing substandard care to children in a developing nation is an unacceptable breach of medical ethics, regardless of the local standards of care.In response to these allegations, Christine Stabell Benn has defended the trial, maintaining that the study adheres to the national policy of Guinea-Bissau and has been vetted by the appropriate national ethics committee. She asserts that no child is being denied a treatment they would otherwise have received under current local guidelines.Further developments emerged from the University of Southern Denmark, where the dean of the faculty of health sciences, Jakob Grauslund, stated that he granted approval for the revised study on October 7, 2026. Grauslund explained that the decision followed an independent ethical assessment by the university's internal committee. He noted that because the study had already received approval from a foreign ethics panel in Guinea-Bissau, Danish law prevented national or regional committees from conducting their own separate reviews.Despite the university's approval, the project has faced hurdles in obtaining external validation. The university reportedly reached out to the World Health Organization's Research Ethics Review Committee and the European Network of Research Ethics Committees for independent reviews, but both organizations stated they were unable to provide such assessments. Currently, the trial remains in a state of limbo as the researchers await final authorization from the national authorities in Guinea-Bissau.The intersection of political influence from the Department of Health and Human Services and the shifting priorities of the CDC continues to raise questions about the future of global health security funding and the ethical boundaries of international clinical research.